Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzheng Yangxin decoction for heart failure with preserved ejection fraction
ChiCTR2400087293Phase 2Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Jul 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fuzheng Yangxin Decoction in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Peak oxygen uptake. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Fuzheng Yangxin Decoction
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR2400087293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087293.